Allogeneic Mesenchymal Stem Cells for Immune Balance in Frailty
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-ischemic dilated cardiomyopathy and aging frailty, characterized by immune dysregulation and chronic inflammation, lack effective treatments, and mesenchymal stem cells have suppressive effects on the immune system, complicating their therapeutic use.
Innovation Solution
Administering therapeutically effective amounts of isolated allogeneic human mesenchymal stem cells to modulate immune markers, including CD19+, CD27−, IgD− exhausted B cells, CD19+, CD27high switched memory B cells, CD3+, CD69+ early activated T-cells, CD3+, CD25+ chronic activated T-cells, CD45RA+, CCR7− Temra cells, and TNF-α levels, to restore immune balance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are administered to treat non-ischemic dilated cardiomyopathy and aging frailty, then immune function is improved and immune markers are modulated, but the suppressive effects on the immune system complicate therapeutic use
Solution Approach 1:
The patent changes the parameters of mesenchymal stem cell therapy by administering specific doses (e.g., 100 million cells) at defined time intervals (e.g., monthly for 3-6 months) to achieve optimal immune modulation while minimizing suppressive effects. This parameter optimization resolves the contradiction between improving immune function and managing therapeutic complexity.
Solution Approach 2:
The patent employs monitoring of immune markers (CD19+, CD27−, IgD− exhausted B cells, CD19+, CD27high switched memory B cells, CD3+, CD69+ early activated T-cells, CD3+, CD25+ chronic activated T-cells, CD45RA+, CCR7− Temra cells, and TNF-α levels) to assess treatment response and adjust therapy accordingly. This feedback mechanism allows dynamic optimization of the therapeutic approach, resolving the complexity of managing immune suppression while achieving immune improvement.
2Reliability
If mesenchymal stem cells modulate immune markers to restore immune balance, then immune dysregulation is improved, but the mechanism of action involves complex interactions with multiple immune cell types and cytokines
Solution Approach 1:
The patent leverages the multi-functional nature of mesenchymal stem cells to simultaneously modulate multiple immune markers and cell types (B cells, T cells, cytokines) with a single therapeutic agent. This universal approach simplifies the overall treatment strategy despite the complex underlying mechanisms, as one cell type performs multiple immunomodulatory functions.
Solution Approach 2:
The patent uses mesenchymal stem cells as intermediary cells that mediate immune modulation through multiple pathways including direct cell-to-cell contact, secretion of cytokines, and induction of regulatory T cells. These intermediary mechanisms allow the stem cells to restore immune balance by acting as a bridge between different immune components, managing the complexity through a central mediating agent.
3Reliability
If allogeneic mesenchymal stem cells are used to treat immune dysregulation, then therapeutic effectiveness is enhanced, but rejection and immunogenicity risks increase
Solution Approach 1:
The patent optimizes parameters of allogeneic stem cell therapy including donor selection criteria, cell processing methods, and administration protocols to minimize immunogenicity while maintaining therapeutic effectiveness. By carefully controlling these parameters, the patent achieves effective immune modulation without significant rejection risks.
Solution Approach 2:
The patent converts the potential harmful effect of allogeneic cell immunogenicity into a beneficial outcome by utilizing the immune-modulating properties of mesenchymal stem cells. The stem cells' ability to regulate immune responses is harnessed to treat immune dysregulation, and any minor immune reactions are actually part of the therapeutic mechanism rather than adverse effects.
Data Source
AI summary
The present invention provides a method of treating subjects with non-ischemic dilated cardiomyopathy by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells. The present invention also provides a method of treating subjects with symptoms of aging frailty by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells.